These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15468129)

  • 21. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S36-42. PubMed ID: 23519303
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using the rate of positive high-risk HPV test results for ASC-US together with the ASC-US/SIL ratio in evaluating the performance of cytopathologists.
    Cibas ES; Zou KH; Crum CP; Kuo F
    Am J Clin Pathol; 2008 Jan; 129(1):97-101. PubMed ID: 18089494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of Human Papillomavirus Genotyping for Triage of Patients with Atypical Squamous Cells of Undetermined Significance by Cervical Cytology.
    Lee B; Suh DH; Kim K; No JH; Kim YB
    Anticancer Res; 2015 Jul; 35(7):4197-202. PubMed ID: 26124378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Knowledge of Patients' Human Papillomavirus Status at the Time of Cytologic Review Significantly Affects the Performance of Cervical Cytology in the ATHENA Study.
    Wright TC; Stoler MH; Aslam S; Behrens CM
    Am J Clin Pathol; 2016 Sep; 146(3):391-8. PubMed ID: 27543984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study.
    Stoler MH; Wright TC; Sharma A; Apple R; Gutekunst K; Wright TL;
    Am J Clin Pathol; 2011 Mar; 135(3):468-75. PubMed ID: 21350104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).
    Carozzi FM; Iossa A; Scalisi A; Sideri M; Andersson KL; Confortini M; Del Mistro A; Maina G; Ronco G; Raggi P; Schiboni ML; Zappa M; Giorgi Rossi P
    Epidemiol Prev; 2015; 39(3 Suppl 1):84-90. PubMed ID: 26405780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A study of cervical cancer screening algorithms].
    Zhao FH; Zhang WH; Pan QJ; Zhang X; Chen W; Liu B; Ma JF; Hu SY; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):420-4. PubMed ID: 20819481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of high-risk human papillomavirus testing in the screening and management of cervical cancer precursors].
    Jin Y; Pan LY
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):691-6. PubMed ID: 18051730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
    Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
    Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atypical squamous cells of undetermined significance-favour reactive compared to atypical squamous cells of undetermined significance-favour dysplasia: association with cervical intraepithelial lesions and human papillomavirus infection.
    Giovannelli L; Capra G; Lama A; Bustinto T; Genco A; Valenti FM; Pinto G; Matranga D; Ammatuna P
    J Clin Virol; 2005 Aug; 33(4):281-6. PubMed ID: 16036177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women-A cohort study.
    Westre B; Giske A; Guttormsen H; Wergeland Sørbye S; Skjeldestad FE
    PLoS One; 2019; 14(11):e0221546. PubMed ID: 31689301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
    Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
    Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.